Skip to content

Dexlansoprazole Absorption and Marginal Ulceration After Gastric Bypass

Prospective, Monocentric Study of Dexlansoprazole Absorption Preoperative and 6 and 12 Months After Proximal Roux-en-Y Gastric Bypass Surgery and of the Incidence of Marginal Ulcers 6 and 12 Months After Surgery

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04423588
Enrollment
0
Registered
2020-06-09
Start date
2022-01-01
Completion date
2022-09-30
Last updated
2026-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgery

Keywords

Proton Pump Inhibitor

Brief summary

In Switzerland, the most commonly performed bariatric procedure is the proximal Roux-en-y gastric Bypass surgery. Since marginal ulceration is a known complication after this Operation, a Proton pump Inhibitor (PPI) prophylaxis is prescribed postoperatively. Bariatric surgery may have an impact on the absorption and consequently on the efficacy of drugs. There are only very little data on the pharmacokinetics of PPIs following PRYGB. The aim of this study is to analyze the serum concentration of dexlansoprazole preoperative and after PRYGB surgery in patients taking PPI prophylaxis and to examine the incidence of marginal ulcers postoperatively in the same population.

Detailed description

This prospective, monocentric study includes 30 patients undergoing a proximal Roux-en-Y gastric Bypass surgery and receiving 6 months of postoperative PPI prophylaxis with Dexilant (dexlansoprazole). The aim is to examine if the LPRYGB has an impact on the absorption of dexlansoprazole. Peripheral blood samples from the study participants are obtained at fixed time points after oral Administration of a capsule Dexilant preoperatively as well as 3 and 6 months after surgery. The incidence of marginal ulceration in the same patient population is assessed by upper endoscopy 6 and 12 months after surgery. The surgery, the PPI prophylaxis and the upper endoscopy 12 months post-surgery aren't for study purpose. Data collection is made by measuring serum drug concentration, patient questionnaires, pill count and upper endoscopy.

Interventions

DIAGNOSTIC_TESTdexlansoprazole serum concentration

6 blood samples are collected at fixed time Points after oral Administration of 1 dose of dexilant at regular patients visits preoperatively and 3 and 6 months post-surgery.

DIAGNOSTIC_TESTupper endoscopy

6 and 12 months after surgery the occurrence of marginal ulcers in the same Patient Group is examined by upper endoscopy. The 12-month endoscopy is part of the Routine postoperative diagnosis, the 6-month endoscopy is for study purpose.

Sponsors

Spital Limmattal Schlieren
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Informed consent for study and surgery as documented by signature * Male and Female Patients over 18 years old eligible for bariatric surgery at the Department of General Surgery, Limmattal Hospital, according to criteria of the Swiss Study Group for Morbid Obesity (SMOB) and international Guidelines * BMI ≥ 35 * Failure of conservative Treatment for 2 years * Type of surgery: LPRYGB * Helicobacter pylori negative * Smoker (≥ 1 cigarette daily) * Women in reproductive Age: negative pregnancy test

Exclusion criteria

* Contraindication for a bariatric surgery according to SMOB-criteria * Contraindication for PPIs * Pregnant or breastfeeding women * Pre- or intraoperative decision for other type of surgery than LPRYGB * Active malignancy * Chronic liver disease Child-Pugh B or C * Abuse of drugs or alcohol * Suspect of non-compliance

Design outcomes

Primary

MeasureTime frameDescription
Change of dexlansoprazole Serum concentration3 monthsDetermination of the dexlansoprazole concentration (ng/ml) in the participants blood at time 0, 60, 90, 120, 210, 300 min after having swallowed a Dosis of dexilant preoperatively and 3 months after surgery

Secondary

MeasureTime frameDescription
Incidence of Marginal ulceration6 monthsStudy of the incidence of marginal ulcers in the participants 6 months after surgery

Contacts

PRINCIPAL_INVESTIGATORUrs Zingg, Prof. Dr. med.

Chefarzt Chirurgie, Limmattal Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 10, 2026